Search details
1.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Article
in English
| MEDLINE | ID: mdl-36652354
2.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Lancet Oncol
; 24(7): 772-782, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37276871
3.
Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
Br J Surg
; 109(1): 61-70, 2021 12 17.
Article
in English
| MEDLINE | ID: mdl-34378010
4.
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis.
Br J Cancer
; 123(3): 362-368, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32433600
5.
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Invest New Drugs
; 37(3): 584-590, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30324344
6.
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Invest New Drugs
; 36(1): 163-169, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28782087
7.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Invest New Drugs
; 36(3): 496-502, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29192354
8.
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Invest New Drugs
; 36(4): 732-741, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29616439
9.
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Br J Cancer
; 116(5): 561-567, 2017 Feb 28.
Article
in English
| MEDLINE | ID: mdl-28081540
10.
Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Gastric Cancer
; 18(2): 346-53, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-24832201
11.
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Target Oncol
; 19(1): 41-49, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38108953
12.
Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.
Int J Surg
; 2024 Mar 28.
Article
in English
| MEDLINE | ID: mdl-38537071
13.
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
Invest New Drugs
; 31(3): 616-22, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-22695940
14.
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 13(2): 181-8, 2012 Feb.
Article
in English
| MEDLINE | ID: mdl-22192731
15.
Epithelial-Mesenchymal Transition Phenotype and Peritumoral Immune Cell Infiltration in Advanced Biliary Tract Cancer.
Anticancer Res
; 43(2): 645-652, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36697100
16.
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Cancer Res Treat
; 55(3): 956-968, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36915253
17.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 41(11): 2007-2019, 2023 04 10.
Article
in English
| MEDLINE | ID: mdl-36521097
18.
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure.
Invest New Drugs
; 30(4): 1703-8, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-21234641
19.
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Invest New Drugs
; 30(1): 306-15, 2012 Feb.
Article
in English
| MEDLINE | ID: mdl-20839031
20.
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Invest New Drugs
; 30(2): 819-27, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-21104107